Paper17538165
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
Herrmann R and 21 others. J Clin Oncol, 2007. Cited by 492 papers, by iCite.
Cite this record
ConductScience Library. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Papers, record 17538165. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17538165
- Disease
- exocrine pancreatic carcinoma253 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
- PubMed
- Publication types
- Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Deoxycytidine | Major topic |
| Fluorouracil | Major topic |
| Pancreatic Neoplasms | Major topic |
| Capecitabine | |
| Female | |
| Humans | |
| Male | |
| Gemcitabine |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00030732 | Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer | Results |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 17538158 | Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag? | https://conductscience.org/library/papers/17538158 |
Source PubMed
Cited by239
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 492 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42448976 | Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/42448976 | PubMed |
| 41731281 | Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here. | Drugs | 2026 | https://conductscience.org/library/papers/41731281 | PubMed |
| 41569206 | Real World Evidence of Clinical Outcomes of First-Line Chemotherapy in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Patients. | Asian Pac J Cancer Prev | 2026 | https://conductscience.org/library/papers/41569206 | PubMed |
| 41058695 | Development of a nomogram integrating immune checkpoints, fibrosis indicators, and clinicopathological characteristics to predict overall survival in pancreatic cancer: a retrospective analysis. | Front Immunol | 2025 | https://conductscience.org/library/papers/41058695 | PubMed |
| 40806185 | Advances in the Management of Pancreatic Cancer: Current Strategies and Emerging Therapies. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40806185 | PubMed |
| 40075310 | Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40075310 | PubMed |
| 40004658 | Current and Emerging Treatment Options for Pancreatic Cancer: A Comprehensive Review. | J Clin Med | 2025 | https://conductscience.org/library/papers/40004658 | PubMed |
| 39712186 | Nomogram for predicting post-progression-free survival in patients with recurrent pancreatic ductal adenocarcinoma after radical surgery: a retrospective analysis. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/39712186 | PubMed |
| 39635901 | Chemotherapy and radiotherapy for advanced pancreatic cancer. | Cochrane Database Syst Rev | 2024 | https://conductscience.org/library/papers/39635901 | PubMed |
| 39551595 | Variability of quality-of-life measurements and reporting in randomised controlled trials of pancreatic cancer: a systematic review. | BMJ Open | 2024 | https://conductscience.org/library/papers/39551595 | PubMed |
| 39390609 | Consensus, debate, and prospective on pancreatic cancer treatments. | J Hematol Oncol | 2024 | https://conductscience.org/library/papers/39390609 | PubMed |
| 39330013 | Systemic Therapy for Metastatic Pancreatic Cancer-Current Landscape and Future Directions. | Curr Oncol | 2024 | https://conductscience.org/library/papers/39330013 | PubMed |
| 38681566 | Efficacy and safety of first-line chemotherapies for patients with advanced pancreatic ductal adenocarcinoma: A systematic review and network meta-analysis. | Heliyon | 2024 | https://conductscience.org/library/papers/38681566 | PubMed |
| 37869244 | Folfirinox vs. Gemcitabine + Nab-Paclitaxel as the First-Line Treatment for Pancreatic Cancer: A Systematic Review and Meta-Analysis. | World J Oncol | 2023 | https://conductscience.org/library/papers/37869244 | PubMed |
| 37007078 | Multidisciplinary team diagnosis and treatment of pancreatic cancer: Current landscape and future prospects. | Front Oncol | 2023 | https://conductscience.org/library/papers/37007078 | PubMed |
| 36235333 | Chemical Constituents of Callistemon subulatus and Their Anti-Pancreatic Cancer Activity against Human PANC-1 Cell Line. | Plants (Basel) | 2022 | https://conductscience.org/library/papers/36235333 | PubMed |
| 36092340 | The efficacy and safety of gemcitabine-based combination therapy vs. gemcitabine alone for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis. | J Gastrointest Oncol | 2022 | https://conductscience.org/library/papers/36092340 | PubMed |
| 35852758 | Recent Update on Active Biological Molecules in Generating the Anticancerous Therapeutic Potential of Garcinia mangostana. | Appl Biochem Biotechnol | 2022 | https://conductscience.org/library/papers/35852758 | PubMed |
| 35099549 | Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis. | JAMA Netw Open | 2022 | https://conductscience.org/library/papers/35099549 | PubMed |
| 35052828 | Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine. | Biomedicines | 2022 | https://conductscience.org/library/papers/35052828 | PubMed |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CAPECITABINE | CHEMBL1773 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1773 | ChEMBL |
| GEMCITABINE | CHEMBL888 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL888 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17538165
GET https://conductscience.org/api/papers/v1/17538165/authors?page=2